Johnson Matthey (JM; London, UK) says it has entered into a five-year supply agreement with Sarepta Therapeutics (Andover, Massachusetts), a biopharmaceutical company.
According to the terms of the agreement, JM will continue to provide regulatory starting materials to support Sarepta’s programs for phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO), used for the treatment of Duchenne muscular dystrophy, the company says.
JM’s innovator products and solutions business that provides custom development and manufacturing (CDMO) services will produce these synthetic regulatory starting materials at its facilities at West Deptford, New Jersey, and Devens, Massachusetts, using their commercial-scale production trains, the company says.
The new agreement strengthens the relationship between the two companies. “Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta’s mission of engineering precision medicine for rare, devastating diseases,” says Alex Zahiri, vice president/innovator products and solutions, CDMO business at JM.
By: Sotirios Frantzanas
Source: Chemical Week
3M and Dow have announced they are cutting thousands of roles from their global workforces in response to economic pressures. Dow has said it will cut 2,000 jobs across its global workforce (around 5%) in a bid to save US$1bn in 2023. The company says it will also cut costs by shutting down “select assets”, though it did not note where it would halt operations.
Sweden’s state mining firm has discovered what could be Europe’s largest rare earths deposit, and says it could help the bloc reduce its reliance on imports of minerals needed to manufacture clean technologies and meet climate targets.
Henkel and Avantium have been partners since 2019, when Henkel joined the PEFerence consortium. This consortium of partners, coordinated by Avantium, aims to establish an innovative supply chain for FDCA and PEF (polyethylene furanoate).